Chan Kenny, Testa Madalena, McCluskey Peter
Department of Ophthalmology, Liverpool Hospital, Liverpool, New South Wales, Australia.
J Ocul Pharmacol Ther. 2007 Aug;23(4):372-6. doi: 10.1089/jop.2006.0131.
Successful management of glaucoma and ocular hypertension requires patient compliance with the therapeutic regimen. Because ocular discomfort affects compliance, we compared the comfort of brimonidine 0.2%/timolol 0.5% and dorzolamide 2%/timolol 0.5%.
In this single-centre, randomized, double-masked, internally controlled/paired-eye study, 30 subjects without a significant ocular surface disease received brimonidine 0.2%/timolol 0.5% in 1 eye and dorzolamide 2%/timolol 0.5% in the fellow eye. They evaluated discomfort at 30-40 s and 5 min postinstillation.
At 30-40 s, brimonidine 0.2%/timolol 0.5% provided significantly lower mean ocular discomfort scores than dorzolamide 2%/timolol 0.5% (P < 0.0001). This pattern persisted at 5 min but was not statistically significant. Significant differences were seen in the subjects' determination of the more comfortable treatment (P < 0.0001): brimonidine 0.2%/timolol 0.5% was rated as more comfortable than dorzolamide 2%/timolol 0.5% by 80% of subjects at 30-40 s and by 27% at 5 min. Only 10% of subjects at each time point rated dorzolamide 2%/timolol 0.5% as more comfortable. The remaining subjects reported no preference at either time point. No adverse events were reported.
Brimonidine 0.2%/timolol 0.5% was significantly more comfortable than dorzolamide 2%/timolol 0.5% upon instillation. Patients with ocular hypertension or glaucoma may be more compliant with brimonidine 0.2%/timolol 0.5% treatment.
成功管理青光眼和高眼压症需要患者遵守治疗方案。由于眼部不适会影响依从性，我们比较了0.2%溴莫尼定/0.5%噻吗洛尔和2%多佐胺/0.5%噻吗洛尔的舒适度。
在这项单中心、随机、双盲、内部对照/双眼配对研究中，30名无明显眼表疾病的受试者一只眼使用0.2%溴莫尼定/0.5%噻吗洛尔，另一只眼使用2%多佐胺/0.5%噻吗洛尔。他们在滴药后30 - 40秒和5分钟评估不适感。
在30 - 40秒时，0.2%溴莫尼定/0.5%噻吗洛尔的平均眼部不适评分显著低于2%多佐胺/0.5%噻吗洛尔（P < 0.0001）。这种模式在5分钟时持续存在，但无统计学意义。在受试者对更舒适治疗的判定上存在显著差异（P < 0.0001）：在30 - 40秒时，80%的受试者认为0.2%溴莫尼定/0.5%噻吗洛尔比2%多佐胺/0.5%噻吗洛尔更舒适，在5分钟时这一比例为27%。在每个时间点，只有10%的受试者认为2%多佐胺/0.5%噻吗洛尔更舒适。其余受试者在两个时间点均表示无偏好。未报告不良事件。
滴药时，0.2%溴莫尼定/0.5%噻吗洛尔比2%多佐胺/0.5%噻吗洛尔明显更舒适。高眼压症或青光眼患者可能对0.2%溴莫尼定/0.5%噻吗洛尔治疗的依从性更高。
